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cent). Finally, we observed no treatment failures
for chlamydial infection among 57 men who re-
ported not having had sexual intercourse during
follow-up.
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to the editor: 
 
Dragun et al. (Feb. 10 issue)
 
1
 
 pro-
vide provocative data on the role of agonistic an-
giotensin II type 1 (AT
 
1
 
)–receptor antibodies in
patients with steroid-refractory renal-allograft re-
jection. We were surprised by the high incidence of
biopsy-proved acute rejection among their patients
(43 percent), which contrasts with the 15 percent
previously reported with a similar immunosup-
pressive protocol.
 
2,3
 
 In addition, 16 of the 33 pa-
tients with steroid-refractory rejection in the study
by Dragun et al. appeared to have malignant hyper-
tension. The median blood pressure was 153/80
mm Hg in the 10 most recent patients with steroid-
refractory rejection in our medical center, only 1 of
whom had signs of hypertensive encephalopathy.
Finally, information about the original renal dis-
ease of the patients is lacking — a relevant point
because the AT
 
1
 
-receptor antibodies were probably
preexistent. We recently observed that patients who
had the hemolytic–uremic syndrome are prone to
have vascular rejection.
 
4
 
 Moreover, AT
 
1
 
-receptor
antibodies have been described in other microan-
giopathic conditions, such as preeclampsia and
malignant hypertension.
 
5
 
 We propose that the
combination of vascular rejection and AT
 
1
 
-recep-
tor antibodies occurs particularly in patients who
have the hemolytic–uremic syndrome or malignant
hypertension as their original renal disease.
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to the editor: 
 
The incidence of severe hyperten-
sion after renal transplantation is primarily related
to the presence of malignant hypertension in the
pretransplantation period.
 
1
 
 The original disease in-
fluences the outcome of kidney transplantation; in
particular, recipients with malignant hypertension
have poorer graft survival.
 
2 
 
No information, howev-
er, is provided in the article by Dragun et al. about
the original cause of end-stage renal disease, post-
transplantation antihypertensive medication, or
mean blood pressure before and after transplanta-
tion. Such data would be important, since hyperten-
sion was the sole clinical factor discriminating be-
tween the two groups. It was unclear in the paper by
Dragun et al. whether this entity represents a sub-
type of acute rejection or recurrent disease. Pre-
formed AT
 
1
 
-receptor antibodies must have been
present at the time of transplantation in at least
some patients in whom clinical events occurred
within days after transplantation. The failure to
identify low levels of anti-HLA antibodies with sen-
sitive solid-phase assays
 
3,4
 
 as well as levels of anti-
bodies that are non–donor-specific
 
5
 
 may have af-
fected both the accuracy of the subsequent analysis
and the conclusions, which were dependent on the
stratification of patients according to these criteria.
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the authors reply: 
 
Our first patient, who did not
have hypertension, was the recipient of a “full-
house” matched transplant  with no panel reactivi-
ty. Severe vascular rejection, malignant hyperten-
sion, and seizures developed after transplantation.
We were struck by the fact that she had had pre-
eclampsia nearly two decades earlier. We detected
AT
 
1
 
-receptor–activating autoantibodies in this pa-
tient, treated her blood pressure, and rescued the
transplant with plasmapheresis and an AT
 
1
 
-recep-
tor blocker. We next screened serum samples from
all patients with steroid-refractory rejection over a
four-year period for anti-HLA reactivity, donor
specificity, and AT
 
1
 
-receptor antibodies. We mini-
mized selection bias by testing all serum samples
for all variables. We reported reactivity against HLA
antigens in both groups of patients and also indi-
cated that determinations of AT
 
1
 
-receptor antibod-
ies were performed. Although a few patients showed
moderate HLA reactivity, these antibodies lacked
donor specificity, as confirmed by the results of an
HLA-antigen–specific enzyme-linked immunosor-
bent assay.
 
1 
 
C4d-negative biopsy specimens argued
against intragraft adsorption of donor-specific anti-
bodies.
 
2
 
End-stage renal disease was attributed to small,
contracted kidneys in eight patients, in whom no
biopsy was performed before transplantation. Other
causes of end-stage renal disease were autosomal
dominant polycystic kidney disease, juvenile neph-
ronophthisis, focal segmental glomerulosclerosis,
chronic tubulointerstitial nephritis, and, in just one
patient, well-documented hypertensive nephroscle-
rosis. None had end-stage renal disease due to the
hemolytic–uremic syndrome. We believe that spe-
cific causes of end-stage renal disease and the pres-
ence or absence of hypertension before transplan-
tation were not necessarily relevant, although we
cannot prove that assumption with certainty. The
hemolytic–uremic syndrome clearly warrants fur-
ther study.
We documented 119 rejection episodes in 83
of 279 patients during a mean (±SD) of 26.2±15
months of follow-up. Seventy-three patients had a
first rejection within six months after transplanta-
tion, for a rejection rate of 26.2 percent, which is
similar to the rates in the reports cited by the corre-
spondents.
 
3
 
 Most of the patients (13 of 16) did not
have hypertension before vascular rejection oc-
curred. This finding suggests that the post-trans-
plantation hypertension was secondary to rejection.
AT
 
1
 
-receptor antibodies transferred to animals that
had received transplants as part of our study induced
first rejection and then hypertension. We suggest
that the AT
 
1
 
-receptor antibodies mediated hyperten-
sion by augmenting a local intrarenal renin–angio-
tensin system by way of activation of AT
 
1
 
 receptors
in a kidney with vascular rejection.
 
4
 
 However, our
study did not test the relevance of hypertension in
antibody-mediated rejection — an issue that war-
rants further investigation.
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